Adjunctive therapies for severe sepsis

International Journal of Antimicrobial Agents
X WitteboleP F Laterre

Abstract

Severe sepsis-associated mortality may still be improved by earlier recognition, faster and adequate source control, and targeted resuscitation. Patients who may benefit from the administration of drotrecogin alfa (activated) are currently those at high risk of death, and other indications should be better defined by ongoing trials. Use of low-dose steroids for the treatment of severe sepsis must be re-clarified by new studies and should be restricted to patients with refractory septic shock. Trials exploring the role of natural anticoagulants and Toll-like receptor inhibitors are ongoing and should be completed in the coming 3 years. Future trials in severe sepsis should target more homogeneous populations with a well-defined focus of infection and severity, receiving appropriate standard of care, and the tested intervention should be administered in a timely fashion according to the expected host response.

References

Nov 11, 1982·The New England Journal of Medicine·E J ZieglerA I Braude
Jan 6, 1999·Critical Care Medicine·G FriedmanJ L Vincent
Jan 17, 2002·The New England Journal of Medicine·E RiversUNKNOWN Early Goal-Directed Therapy Collaborative Group
Aug 21, 2002·JAMA : the Journal of the American Medical Association·Djillali AnnaneEric Bellissant
Sep 27, 2002·The New England Journal of Medicine·H Shaw WarrenRobert S Munford
Apr 18, 2003·The New England Journal of Medicine·Greg S MartinMarc Moss
Jul 10, 2003·JAMA : the Journal of the American Medical Association·Edward AbrahamUNKNOWN OPTIMIST Trial Study Group
Jul 12, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E Wesley ElyGordon R Bernard
Sep 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cheol-In KangKang-Won Choe
Oct 16, 2003·JAMA : the Journal of the American Medical Association·Simon J FinneyTimothy W Evans
Mar 12, 2005·QJM : Monthly Journal of the Association of Physicians·N ProulxS Kravcik
Jul 5, 2005·Critical Care Clinics·Steven P LaRosa, Steven M Opal
Jul 12, 2005·Intensive Care Medicine·Ritesh Agarwal, Dheeraj Gupta
Oct 11, 2005·Critical Care Medicine·Mitchell M LevyMark D Williams
Feb 3, 2006·The New England Journal of Medicine·Greet Van den BergheRoger Bouillon
Sep 13, 2007·Thrombosis and Haemostasis·Alexander D CornetA B Johan Groeneveld
Dec 13, 2007·Critical Care Medicine·K Georg KreymannStefan Kluge
Dec 13, 2007·Critical Care Medicine·Karl WerdanUNKNOWN Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group
Jan 11, 2008·The New England Journal of Medicine·Simon Finfer
Feb 16, 2008·British Journal of Anaesthesia·F GaoD R Thickett
Feb 29, 2008·The New England Journal of Medicine·James A RussellUNKNOWN VASST Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.